V
Vape Co. Eyes Intervention In FDA E-Cigarette Suit
law36010/1/2026
Page 7 of 51
Sort news
V
law36010/1/2026
Vape Co. Eyes Intervention In FDA E-Cigarette Suit
‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.
nypost10/1/2026
J
JECT Supports Breast Cancer Awareness Month With a Giveback Program and Women's Health and Wellness Panel
This Breast Cancer Awareness Month, leading medical aesthetics brand, JECT, is supporting the fight against breast cancer and empowering women to advocate for their health. Throughout October, JECT is donating $1 from every treatment performed to the Breast Cancer Research Foundation (BCRF), with BCRF information displayed in all locations to encourage community donations. On Wednesdays in October, the JECT team will wear pink to keep breast cancer awareness top of mind, and breast cancer
financialcontent10/1/2026
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in ...
-- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients --
postregister10/1/2026
STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
Questions about the durability of an experimental Huntington's disease therapy matter to Wall Street. They matter less to those directly affected by the disease.
statnews10/1/2026
STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await
The small biotech company Invivyd is developing an injectable, low-dose monoclonal antibody to protect against Covid.
statnews10/1/2026
P
Public health director answers questions about the measles vaccine
thegazette_com10/1/2026
L
Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab Results provide prospective clinical data on the use of eptinezumab in adults with migraine following...
cision10/1/2026
STAT+: Sanofi, Regeneron expand partnership after Dupixent success
Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
statnews10/1/2026
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analysts, shares in Boehringer’s partner Zealand Pharma fell 12% in early trading in Denmark.
fiercebiotech10/1/2026